Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-03

AUTHORS

Stephan H. Duda, Gunnar Tepe, Mohan Bala, Oliver Luz, Gerhard Ziemer, Kenneth Ouriel, Benjamin Pusich, Jakub Wiskirchen, Claus D. Claussen, Kurt Banz

ABSTRACT

Background and objective: Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration.Study design: A post-hoc economic analysis was performed using clinical data and inpatient resource utilisation derived from the prospective comparative phase II Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis (PROMPT) pilot study. Study endpoints were amputation-free survival and survival without open surgery or major amputation after 90 days, and the rate of major complications at 30 days.Perspective: Third-party payer and the societal perspective.Patients and methods: Seventy patients with lower extremity thrombi were randomised (2: 5 ratio) to urokinase plus placebo or to urokinase plus abciximab. Economically relevant data were retrospectively derived from the clinical study database from a specific evaluation of patient records and from expert opinion.Results: From the viewpoint of the society, average total per-patient direct and indirect costs accruing over 3 months were more favourable for treatment with abciximab plus urokinase than for urokinase alone [9723 euros (EUR) vs EUR10 322; 2000 values], despite higher initial hospitalisation costs of the combination therapy. Abciximab plus urokinase was the dominant strategy at 3 months due to a clinically higher rate of survival without amputation or bypass surgery coupled with a lower average per-patient cost. From the perspective of the third-party payer, treatment with abciximab plus urokinase was economically also superior to urokinase alone (EUR8773 vs EUR9663).Conclusions: Based on the preliminary findings of the PROMPT trial, the use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase alone, in terms of clinical and economic outcomes. Further trials are needed to confirm these clinical and economic findings.The preliminary clinical benefits experienced by patients treated with abciximab plus urokinase in the PROMPT trial translated into cost savings in terms of reduced direct medical costs at 3 months. These cost savings more than offset the cost of abciximab. The use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase-alone in terms of clinical and economic outcomes, but further trials are needed to confirm the these clinical and economic findings. More... »

PAGES

203-213

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200220030-00006

DOI

http://dx.doi.org/10.2165/00019053-200220030-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011150690

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11929350


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abciximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amputation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arterial Occlusive Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrinolytic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoglobulin Fab Fragments", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasminogen Activators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urokinase-Type Plasminogen Activator", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duda", 
        "givenName": "Stephan H.", 
        "id": "sg:person.011641132444.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011641132444.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tepe", 
        "givenName": "Gunnar", 
        "id": "sg:person.01235146031.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235146031.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Health Economics, Centocor, Malvern, Pennsylvania, USA", 
          "id": "http://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Department of Health Economics, Centocor, Malvern, Pennsylvania, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bala", 
        "givenName": "Mohan", 
        "id": "sg:person.01164000550.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164000550.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luz", 
        "givenName": "Oliver", 
        "id": "sg:person.01105213147.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105213147.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Thoracic and Cardiovascular Surgery, University of Tuebingen, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Thoracic and Cardiovascular Surgery, University of Tuebingen, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ziemer", 
        "givenName": "Gerhard", 
        "id": "sg:person.01306577500.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306577500.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ouriel", 
        "givenName": "Kenneth", 
        "id": "sg:person.013070616174.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013070616174.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pusich", 
        "givenName": "Benjamin", 
        "id": "sg:person.0742216731.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742216731.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wiskirchen", 
        "givenName": "Jakub", 
        "id": "sg:person.01142763542.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142763542.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10392.39", 
          "name": [
            "Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Claussen", 
        "givenName": "Claus D.", 
        "id": "sg:person.012561241352.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012561241352.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Outcomes International, Basle, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Outcomes International, Basle, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Banz", 
        "givenName": "Kurt", 
        "id": "sg:person.01025500732.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025500732.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-200119010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021793011", 
          "https://doi.org/10.2165/00019053-200119010-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199916060-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039159215", 
          "https://doi.org/10.2165/00019053-199916060-00009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199610050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048630198", 
          "https://doi.org/10.2165/00019053-199610050-00003"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-03", 
    "datePublishedReg": "2002-03-01", 
    "description": "Background and objective: Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration.Study design: A post-hoc economic analysis was performed using clinical data and inpatient resource utilisation derived from the prospective comparative phase II Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis (PROMPT) pilot study. Study endpoints were amputation-free survival and survival without open surgery or major amputation after 90 days, and the rate of major complications at 30 days.Perspective: Third-party payer and the societal perspective.Patients and methods: Seventy patients with lower extremity thrombi were randomised (2: 5 ratio) to urokinase plus placebo or to urokinase plus abciximab. Economically relevant data were retrospectively derived from the clinical study database from a specific evaluation of patient records and from expert opinion.Results: From the viewpoint of the society, average total per-patient direct and indirect costs accruing over 3 months were more favourable for treatment with abciximab plus urokinase than for urokinase alone [9723 euros (EUR) vs EUR10 322; 2000 values], despite higher initial hospitalisation costs of the combination therapy. Abciximab plus urokinase was the dominant strategy at 3 months due to a clinically higher rate of survival without amputation or bypass surgery coupled with a lower average per-patient cost. From the perspective of the third-party payer, treatment with abciximab plus urokinase was economically also superior to urokinase alone (EUR8773 vs EUR9663).Conclusions: Based on the preliminary findings of the PROMPT trial, the use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase alone, in terms of clinical and economic outcomes. Further trials are needed to confirm these clinical and economic findings.The preliminary clinical benefits experienced by patients treated with abciximab plus urokinase in the PROMPT trial translated into cost savings in terms of reduced direct medical costs at 3 months. These cost savings more than offset the cost of abciximab. The use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase-alone in terms of clinical and economic outcomes, but further trials are needed to confirm the these clinical and economic findings.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200220030-00006", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "peripheral artery occlusions", 
      "use of abciximab", 
      "artery occlusion", 
      "third-party payers", 
      "further trials", 
      "glycoprotein IIb/IIIa receptor inhibitors", 
      "IIb/IIIa receptor inhibitors", 
      "GP IIb/IIIa inhibitors", 
      "amputation-free survival", 
      "IIb/IIIa inhibitors", 
      "lower extremity thrombus", 
      "clinical study database", 
      "initial hospitalisation costs", 
      "cost of abciximab", 
      "acute coronary syndrome", 
      "peripheral arterial occlusion", 
      "direct medical costs", 
      "inpatient resource utilisation", 
      "adjunctive abciximab", 
      "major amputation", 
      "coronary syndrome", 
      "IIIa inhibitors", 
      "bypass surgery", 
      "prompt trial", 
      "study endpoint", 
      "major complications", 
      "open surgery", 
      "arterial occlusion", 
      "receptor antibodies", 
      "hospitalisation costs", 
      "combination therapy", 
      "clinical benefit", 
      "weeks duration", 
      "abciximab", 
      "receptor inhibitors", 
      "clinical data", 
      "patient costs", 
      "patients", 
      "medical costs", 
      "patient records", 
      "pilot study", 
      "societal perspective", 
      "economic outcomes", 
      "study database", 
      "trials", 
      "occlusion", 
      "indirect costs", 
      "adjunct", 
      "thrombolysis", 
      "months", 
      "urokinase", 
      "cost savings", 
      "surgery", 
      "amputation", 
      "survival", 
      "favorable strategy", 
      "high rate", 
      "preliminary findings", 
      "economic findings", 
      "outcomes", 
      "specific evaluation", 
      "expert opinion", 
      "treatment", 
      "inhibitors", 
      "days", 
      "resource utilisation", 
      "findings", 
      "payers", 
      "placebo", 
      "complications", 
      "thrombus", 
      "syndrome", 
      "therapy", 
      "relevant data", 
      "endpoints", 
      "antibodies", 
      "duration", 
      "rate", 
      "economic impact", 
      "dominant strategy", 
      "use", 
      "strategies", 
      "data", 
      "records", 
      "study", 
      "evaluation", 
      "benefits", 
      "background", 
      "database", 
      "objective", 
      "analysis", 
      "utilisation", 
      "opinion", 
      "impact", 
      "cost", 
      "economic analysis", 
      "terms", 
      "perspective", 
      "values", 
      "society", 
      "method", 
      "savings", 
      "order", 
      "viewpoint", 
      "economic value", 
      "IIIa receptor inhibitors", 
      "prospective comparative phase II Platelet Receptor Antibodies", 
      "comparative phase II Platelet Receptor Antibodies", 
      "phase II Platelet Receptor Antibodies", 
      "II Platelet Receptor Antibodies", 
      "Platelet Receptor Antibodies", 
      "Peripheral Artery Thrombosis (PROMPT) pilot study", 
      "Artery Thrombosis (PROMPT) pilot study", 
      "Thrombosis (PROMPT) pilot study", 
      "extremity thrombi", 
      "higher initial hospitalisation costs", 
      "subacute peripheral artery occlusions", 
      "preliminary clinical benefits", 
      "Subacute Peripheral Arterial Occlusion"
    ], 
    "name": "Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion", 
    "pagination": "203-213", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011150690"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200220030-00006"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11929350"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200220030-00006", 
      "https://app.dimensions.ai/details/publication/pub.1011150690"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_361.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200220030-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200220030-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200220030-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200220030-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200220030-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

335 TRIPLES      22 PREDICATES      166 URIs      155 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200220030-00006 schema:about N129301125f274d918699120423ccf035
2 N207774a7a49841978491654001f305c0
3 N28f4ce458c1f43fa94d8d66fdfae35f7
4 N2b254707a55e4f48b459aa22b49b4735
5 N30363935f3c74e2d8d323324674dd9a0
6 N3c06f9d0a03048e2934388efc0895acf
7 N4aa395db3514489d8df35fa96a2830a0
8 N531b5cf3455340d59603877bca343e71
9 N6731e013f18e4140b0ac9d66df9612cc
10 N679db1a9b0f04716b42e834d79335c8f
11 N78dbd14de83d43f5b91bef6efdbd2848
12 N7ba739b3962d4efcb7bbe80476f55918
13 N87cbb301ba0144808faf9b8a793f3d56
14 Na8bec0438aaa443ab8660c634edb725b
15 Ncefef9c3092947df979f445916670a42
16 Nd6a49a4d853d47fabc8cb663740edb05
17 Ndfa8302d17244ce8aa9336515940e448
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nf3a0138fb8dc48c2a6fb1fef34eec81c
21 schema:citation sg:pub.10.2165/00019053-199610050-00003
22 sg:pub.10.2165/00019053-199916060-00009
23 sg:pub.10.2165/00019053-200119010-00003
24 schema:datePublished 2002-03
25 schema:datePublishedReg 2002-03-01
26 schema:description Background and objective: Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration.Study design: A post-hoc economic analysis was performed using clinical data and inpatient resource utilisation derived from the prospective comparative phase II Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis (PROMPT) pilot study. Study endpoints were amputation-free survival and survival without open surgery or major amputation after 90 days, and the rate of major complications at 30 days.Perspective: Third-party payer and the societal perspective.Patients and methods: Seventy patients with lower extremity thrombi were randomised (2: 5 ratio) to urokinase plus placebo or to urokinase plus abciximab. Economically relevant data were retrospectively derived from the clinical study database from a specific evaluation of patient records and from expert opinion.Results: From the viewpoint of the society, average total per-patient direct and indirect costs accruing over 3 months were more favourable for treatment with abciximab plus urokinase than for urokinase alone [9723 euros (EUR) vs EUR10 322; 2000 values], despite higher initial hospitalisation costs of the combination therapy. Abciximab plus urokinase was the dominant strategy at 3 months due to a clinically higher rate of survival without amputation or bypass surgery coupled with a lower average per-patient cost. From the perspective of the third-party payer, treatment with abciximab plus urokinase was economically also superior to urokinase alone (EUR8773 vs EUR9663).Conclusions: Based on the preliminary findings of the PROMPT trial, the use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase alone, in terms of clinical and economic outcomes. Further trials are needed to confirm these clinical and economic findings.The preliminary clinical benefits experienced by patients treated with abciximab plus urokinase in the PROMPT trial translated into cost savings in terms of reduced direct medical costs at 3 months. These cost savings more than offset the cost of abciximab. The use of abciximab as an adjunct to urokinase in patients with subacute peripheral artery occlusions may be the favourable strategy compared with urokinase-alone in terms of clinical and economic outcomes, but further trials are needed to confirm the these clinical and economic findings.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N6cc5be2a951d4bbca1d3f9c187b700ec
31 Nbe220ff579034a8186a243161272ea8f
32 sg:journal.1102812
33 schema:keywords Artery Thrombosis (PROMPT) pilot study
34 GP IIb/IIIa inhibitors
35 II Platelet Receptor Antibodies
36 IIIa inhibitors
37 IIIa receptor inhibitors
38 IIb/IIIa inhibitors
39 IIb/IIIa receptor inhibitors
40 Peripheral Artery Thrombosis (PROMPT) pilot study
41 Platelet Receptor Antibodies
42 Subacute Peripheral Arterial Occlusion
43 Thrombosis (PROMPT) pilot study
44 abciximab
45 acute coronary syndrome
46 adjunct
47 adjunctive abciximab
48 amputation
49 amputation-free survival
50 analysis
51 antibodies
52 arterial occlusion
53 artery occlusion
54 background
55 benefits
56 bypass surgery
57 clinical benefit
58 clinical data
59 clinical study database
60 combination therapy
61 comparative phase II Platelet Receptor Antibodies
62 complications
63 coronary syndrome
64 cost
65 cost of abciximab
66 cost savings
67 data
68 database
69 days
70 direct medical costs
71 dominant strategy
72 duration
73 economic analysis
74 economic findings
75 economic impact
76 economic outcomes
77 economic value
78 endpoints
79 evaluation
80 expert opinion
81 extremity thrombi
82 favorable strategy
83 findings
84 further trials
85 glycoprotein IIb/IIIa receptor inhibitors
86 high rate
87 higher initial hospitalisation costs
88 hospitalisation costs
89 impact
90 indirect costs
91 inhibitors
92 initial hospitalisation costs
93 inpatient resource utilisation
94 lower extremity thrombus
95 major amputation
96 major complications
97 medical costs
98 method
99 months
100 objective
101 occlusion
102 open surgery
103 opinion
104 order
105 outcomes
106 patient costs
107 patient records
108 patients
109 payers
110 peripheral arterial occlusion
111 peripheral artery occlusions
112 perspective
113 phase II Platelet Receptor Antibodies
114 pilot study
115 placebo
116 preliminary clinical benefits
117 preliminary findings
118 prompt trial
119 prospective comparative phase II Platelet Receptor Antibodies
120 rate
121 receptor antibodies
122 receptor inhibitors
123 records
124 relevant data
125 resource utilisation
126 savings
127 societal perspective
128 society
129 specific evaluation
130 strategies
131 study
132 study database
133 study endpoint
134 subacute peripheral artery occlusions
135 surgery
136 survival
137 syndrome
138 terms
139 therapy
140 third-party payers
141 thrombolysis
142 thrombus
143 treatment
144 trials
145 urokinase
146 use
147 use of abciximab
148 utilisation
149 values
150 viewpoint
151 weeks duration
152 schema:name Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion
153 schema:pagination 203-213
154 schema:productId N552a99d448a04189887985f728990204
155 N756e679d1dc74d4abc4b048570b13a0b
156 Nfc8d1648dd0f49ba84135c3f4ab97d6f
157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011150690
158 https://doi.org/10.2165/00019053-200220030-00006
159 schema:sdDatePublished 2021-12-01T19:14
160 schema:sdLicense https://scigraph.springernature.com/explorer/license/
161 schema:sdPublisher Ne68592b6bb4847ccb8a07453dbcbca45
162 schema:url https://doi.org/10.2165/00019053-200220030-00006
163 sgo:license sg:explorer/license/
164 sgo:sdDataset articles
165 rdf:type schema:ScholarlyArticle
166 N06e6a9e66fe84b8ab5d56c5c1169372f rdf:first sg:person.01025500732.35
167 rdf:rest rdf:nil
168 N06e82af7fc6a4db29cb235b4e20b5a5c rdf:first sg:person.01142763542.89
169 rdf:rest Nb9c821aab7a64a7ea78d1c469a062dc4
170 N086ceaf839a746b29761ca0ca353104d rdf:first sg:person.01105213147.88
171 rdf:rest N3c95bcae77a540eea46d44af2fa6dfe2
172 N11d0fd311d504902a6d82857ee6859ac rdf:first sg:person.013070616174.66
173 rdf:rest N509886c6ebd148f7b2795813397a31d5
174 N129301125f274d918699120423ccf035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Male
176 rdf:type schema:DefinedTerm
177 N207774a7a49841978491654001f305c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged
179 rdf:type schema:DefinedTerm
180 N28f4ce458c1f43fa94d8d66fdfae35f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Fibrinolytic Agents
182 rdf:type schema:DefinedTerm
183 N2b254707a55e4f48b459aa22b49b4735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Treatment Outcome
185 rdf:type schema:DefinedTerm
186 N30363935f3c74e2d8d323324674dd9a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Plasminogen Activators
188 rdf:type schema:DefinedTerm
189 N3c06f9d0a03048e2934388efc0895acf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Urokinase-Type Plasminogen Activator
191 rdf:type schema:DefinedTerm
192 N3c95bcae77a540eea46d44af2fa6dfe2 rdf:first sg:person.01306577500.22
193 rdf:rest N11d0fd311d504902a6d82857ee6859ac
194 N47f8564c08804c1ea0ff3082bb86498d rdf:first sg:person.01235146031.45
195 rdf:rest Nf180f5a70ff74858860d7b58f31ab2a9
196 N4aa395db3514489d8df35fa96a2830a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Abciximab
198 rdf:type schema:DefinedTerm
199 N509886c6ebd148f7b2795813397a31d5 rdf:first sg:person.0742216731.26
200 rdf:rest N06e82af7fc6a4db29cb235b4e20b5a5c
201 N531b5cf3455340d59603877bca343e71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Amputation
203 rdf:type schema:DefinedTerm
204 N552a99d448a04189887985f728990204 schema:name doi
205 schema:value 10.2165/00019053-200220030-00006
206 rdf:type schema:PropertyValue
207 N6731e013f18e4140b0ac9d66df9612cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Aged, 80 and over
209 rdf:type schema:DefinedTerm
210 N679db1a9b0f04716b42e834d79335c8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Middle Aged
212 rdf:type schema:DefinedTerm
213 N6cc5be2a951d4bbca1d3f9c187b700ec schema:issueNumber 3
214 rdf:type schema:PublicationIssue
215 N756e679d1dc74d4abc4b048570b13a0b schema:name pubmed_id
216 schema:value 11929350
217 rdf:type schema:PropertyValue
218 N78dbd14de83d43f5b91bef6efdbd2848 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Arterial Occlusive Diseases
220 rdf:type schema:DefinedTerm
221 N7ba739b3962d4efcb7bbe80476f55918 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Survival Analysis
223 rdf:type schema:DefinedTerm
224 N87cbb301ba0144808faf9b8a793f3d56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Female
226 rdf:type schema:DefinedTerm
227 Na8bec0438aaa443ab8660c634edb725b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Adult
229 rdf:type schema:DefinedTerm
230 Nb9c821aab7a64a7ea78d1c469a062dc4 rdf:first sg:person.012561241352.36
231 rdf:rest N06e6a9e66fe84b8ab5d56c5c1169372f
232 Nbe220ff579034a8186a243161272ea8f schema:volumeNumber 20
233 rdf:type schema:PublicationVolume
234 Ncefef9c3092947df979f445916670a42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Humans
236 rdf:type schema:DefinedTerm
237 Nd6a49a4d853d47fabc8cb663740edb05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name Immunoglobulin Fab Fragments
239 rdf:type schema:DefinedTerm
240 Ndfa8302d17244ce8aa9336515940e448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Antibodies, Monoclonal
242 rdf:type schema:DefinedTerm
243 Ne68592b6bb4847ccb8a07453dbcbca45 schema:name Springer Nature - SN SciGraph project
244 rdf:type schema:Organization
245 Nf180f5a70ff74858860d7b58f31ab2a9 rdf:first sg:person.01164000550.98
246 rdf:rest N086ceaf839a746b29761ca0ca353104d
247 Nf3a0138fb8dc48c2a6fb1fef34eec81c rdf:first sg:person.011641132444.51
248 rdf:rest N47f8564c08804c1ea0ff3082bb86498d
249 Nfc8d1648dd0f49ba84135c3f4ab97d6f schema:name dimensions_id
250 schema:value pub.1011150690
251 rdf:type schema:PropertyValue
252 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
253 schema:name Medical and Health Sciences
254 rdf:type schema:DefinedTerm
255 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
256 schema:name Clinical Sciences
257 rdf:type schema:DefinedTerm
258 sg:journal.1102812 schema:issn 1170-7690
259 1179-2027
260 schema:name PharmacoEconomics
261 schema:publisher Springer Nature
262 rdf:type schema:Periodical
263 sg:person.01025500732.35 schema:affiliation grid-institutes:None
264 schema:familyName Banz
265 schema:givenName Kurt
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025500732.35
267 rdf:type schema:Person
268 sg:person.01105213147.88 schema:affiliation grid-institutes:grid.10392.39
269 schema:familyName Luz
270 schema:givenName Oliver
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105213147.88
272 rdf:type schema:Person
273 sg:person.01142763542.89 schema:affiliation grid-institutes:grid.10392.39
274 schema:familyName Wiskirchen
275 schema:givenName Jakub
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142763542.89
277 rdf:type schema:Person
278 sg:person.01164000550.98 schema:affiliation grid-institutes:grid.497530.c
279 schema:familyName Bala
280 schema:givenName Mohan
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164000550.98
282 rdf:type schema:Person
283 sg:person.011641132444.51 schema:affiliation grid-institutes:grid.10392.39
284 schema:familyName Duda
285 schema:givenName Stephan H.
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011641132444.51
287 rdf:type schema:Person
288 sg:person.01235146031.45 schema:affiliation grid-institutes:grid.10392.39
289 schema:familyName Tepe
290 schema:givenName Gunnar
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235146031.45
292 rdf:type schema:Person
293 sg:person.012561241352.36 schema:affiliation grid-institutes:grid.10392.39
294 schema:familyName Claussen
295 schema:givenName Claus D.
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012561241352.36
297 rdf:type schema:Person
298 sg:person.01306577500.22 schema:affiliation grid-institutes:grid.10392.39
299 schema:familyName Ziemer
300 schema:givenName Gerhard
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306577500.22
302 rdf:type schema:Person
303 sg:person.013070616174.66 schema:affiliation grid-institutes:grid.239578.2
304 schema:familyName Ouriel
305 schema:givenName Kenneth
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013070616174.66
307 rdf:type schema:Person
308 sg:person.0742216731.26 schema:affiliation grid-institutes:grid.10392.39
309 schema:familyName Pusich
310 schema:givenName Benjamin
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742216731.26
312 rdf:type schema:Person
313 sg:pub.10.2165/00019053-199610050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048630198
314 https://doi.org/10.2165/00019053-199610050-00003
315 rdf:type schema:CreativeWork
316 sg:pub.10.2165/00019053-199916060-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039159215
317 https://doi.org/10.2165/00019053-199916060-00009
318 rdf:type schema:CreativeWork
319 sg:pub.10.2165/00019053-200119010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021793011
320 https://doi.org/10.2165/00019053-200119010-00003
321 rdf:type schema:CreativeWork
322 grid-institutes:None schema:alternateName Outcomes International, Basle, Switzerland
323 schema:name Outcomes International, Basle, Switzerland
324 rdf:type schema:Organization
325 grid-institutes:grid.10392.39 schema:alternateName Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany
326 Division of Thoracic and Cardiovascular Surgery, University of Tuebingen, Tuebingen, Germany
327 schema:name Division of Diagnostic Radiology, Department of Radiology, University of Tuebingen, Dr. Eberhard-Karls-University, Tuebingen, Germany
328 Division of Thoracic and Cardiovascular Surgery, University of Tuebingen, Tuebingen, Germany
329 rdf:type schema:Organization
330 grid-institutes:grid.239578.2 schema:alternateName Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA
331 schema:name Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA
332 rdf:type schema:Organization
333 grid-institutes:grid.497530.c schema:alternateName Department of Health Economics, Centocor, Malvern, Pennsylvania, USA
334 schema:name Department of Health Economics, Centocor, Malvern, Pennsylvania, USA
335 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...